How I Treat Patients with MDS Who Have Been Failed by Hypomethylating Agents
Amy E. DeZern, MD, Johns Hopkins University
Friday, September 8, 2017 10:30 a.m.
Fairmont Chicago, Millennium Park, Chicago, IL
The hypomethylating agents (HMAs) azacitidine and decitabine are the most utilized therapies for higher risk patients with myelodysplastic syndromes as well as for a proportion of lower risk patients requiring more intensive therapies. Unfortunately, there remains a significant proportion of these patients who do not respond (primary failure) or lose their response (secondary failure) and require additional therapies to control their disease. Recently, there have been a number of clinical investigations to determine patient populations more or less likely to HMAs as well as experimental therapies designed for this setting. Dr. DeZern will discuss combination therapies, second line options, and novel therapies at the time of HMA failure, as well as the role of more intensive therapy as a bridge to potential stem cell therapy.
About the Speaker
Amy E. DeZern, MD, is a faculty member in the Division of Hematologic Malignancies at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. She is an active clinical researcher in bone marrow failure syndromes, and her expertise is widely sought for consultations at all stages of these diseases. Dr. DeZern has expertise in diagnosis, clinical management, and treatment of patients with aplastic anemia and myelodysplastic syndromes as well as their clonal evolution to acute myeloid leukemia. Her current research interests include clinical trials of novel agents in myelodysplastic syndromes for newly diagnosed as well as refractory patients. She also conducts trials of bone marrow transplantation in aplastic anemia.
back to top